Immunic (IMUX) director Jon Congleton awarded 50,740 stock options at $10.90

Rhea-AI Filing Summary

IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 50,740 shares of common stock. The options have an exercise price of $10.90 per share and were conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting on June 29, 2026. The options vest in 36 equal monthly installments from March 27, 2026, and expire on March 27, 2036, leaving Congleton with 50,740 options following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Congleton Jon

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	50,740	$0.00	--

Holdings After Transaction: Stock Option — 50,740 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. The options vest in thirty-six (36) equal installments on each monthly anniversary of March 27, 2026.

Key Figures

Options granted: 50,740 options Exercise price: $10.90 per share Expiration date: March 27, 2036 +1 more

4 metrics

Options granted 50,740 options Stock option grant to director Jon Congleton

Exercise price $10.90 per share Stock option exercise price for the grant

Expiration date March 27, 2036 Option term end date

Vesting schedule 36 equal monthly installments Vesting from March 27, 2026

Key Terms

Stock Option, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, vest in thirty-six (36) equal installments

4 terms

Stock Option financial

"Represents options to purchase shares of common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2019 Omnibus Equity Incentive Plan financial

"subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan"

Annual Meeting of Stockholders financial

"obtained at the Company's 2026 Annual Meeting of Stockholders"

vest in thirty-six (36) equal installments financial

"The options vest in thirty-six (36) equal installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:35 PM Accepted by SEC EDGAR 06/29/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.9	06/29/2026		A		50,740(1)		(2)	03/27/2036	Common Stock	50,740	$0.00	50,740	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The options vest in thirty-six (36) equal installments on each monthly anniversary of March 27, 2026.

	/s/ Grant Levine, attorney-in-fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunic (IMUX) director Jon Congleton report in this Form 4?

Jon Congleton reported receiving a grant of stock options for 50,740 shares of Immunic common stock. The options were awarded as compensation, giving him the right to buy shares at a fixed exercise price over a future period.

What are the key terms of Jon Congleton’s Immunic (IMUX) stock options?

The options cover 50,740 shares of Immunic common stock at an exercise price of $10.90 per share. They expire on March 27, 2036, providing a long-term window in which Congleton can choose to exercise them if conditions are favorable.

How do Jon Congleton’s Immunic (IMUX) options vest over time?

The options vest in thirty-six equal monthly installments starting on March 27, 2026. This means a portion of the 50,740 options becomes exercisable each month over three years, encouraging ongoing alignment with Immunic’s long-term performance.

What approvals were required for Jon Congleton’s stock option grant at Immunic (IMUX)?

The grant was conditionally approved by Immunic’s Board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. Stockholders granted this approval at the 2026 Annual Meeting held on June 29, 2026.

How many Immunic (IMUX) options does Jon Congleton hold after this transaction?

Following this grant, Jon Congleton holds 50,740 stock options directly. These options, once vested, allow him to purchase an equal number of Immunic common shares at the fixed exercise price set in the award agreement.